Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial / 中华医学杂志(英文版)
Chinese Medical Journal
; (24): 2199-2205, 2010.
Article
en En
| WPRIM
| ID: wpr-237480
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>BACKGROUND</b>Despite its widespread use in the management of HIV-related cytomegalovirus (CMV) infection, there have been surprisingly few reports of the use of valganciclovir (VGC) in the post-allotransplant setting. So far, no multi-center, non-crossover trial data have been available with the use of this drug as the primary pre-emptive. The present study evaluated the efficacy and safety of VGC for preemptive therapy of CMV infection after allogeneic hematopoietic stem cell transplantation (HSCT).</p><p><b>METHODS</b>From January to April 2007, VGC was adopted in eleven centers in mainland China for pre-emptive therapy of CMV infection in consecutive patients undergoing allogeneic HSCT. Allogeneic HSCT recipients were followed weekly via CMV pp65 antigenemia assay or real-time quantitative polymerase chain reaction (PCR) for detection of CMV-DNA. Patients with a positive assay were treated with VGC, 900 mg P.O. twice a day for 14 days followed by 900 mg P.O. once a day for 14 days after a negative result or the CMV-DNA load was lower.</p><p><b>RESULTS</b>A total of 54 patients (15 siblings, 28 mismatched related donors, 11 unrelated donors) had a positive assay treated with oral VGC. The seroconversion rate was 89% (48/54) as confirmed by a negative assay; six patients failed oral VGC. No significant toxicity was encountered. No case of CMV disease was diagnosed in the responding patients with a median follow-up of 5.3 months after the drug administration.</p><p><b>CONCLUSION</b>Pre-emptive therapy of CMV viraemia with oral VGC is safe and effective in allogeneic HSCT.</p>
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Antivirales
/
Viremia
/
Virología
/
Ganciclovir
/
China
/
Infecciones por Citomegalovirus
/
Trasplante de Células Madre Hematopoyéticas
/
Usos Terapéuticos
/
Quimioterapia
Tipo de estudio:
Clinical_trials
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
País/Región como asunto:
Asia
Idioma:
En
Revista:
Chinese Medical Journal
Año:
2010
Tipo del documento:
Article